Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with 211At Using Implanted Mouse Tumor

Recent introduction of alpha-emitting radionuclides in targeted radionuclide therapy has stimulated the development of new radiopharmaceuticals. Preclinical evaluation using an animal experiment with an implanted tumor model is frequently used to examine the efficiency of the treatment method and to predict the treatment response before clinical trials. Here, we propose a mathematical model for evaluation of the tumor response in an implanted tumor model and apply it to the data obtained from the previous experiment of 211At treatment in a thyroid cancer mouse model. The proposed model is based on the set of differential equations, describing the kinetics of radiopharmaceuticals, the tumor growth, and the treatment response. First, the tumor growth rate was estimated from the control data without injection of 211At. The kinetic behavior of the injected radionuclide was used to estimate the radiation dose profile to the target tumor, which can suppress the tumor growth in a dose-dependent manner. An additional two factors, including the time delay for the reduction of tumor volume and the impaired recovery of tumor regrowth after the treatment, were needed to simulate the temporal changes of tumor size after treatment. Finally, the parameters obtained from the simulated tumor growth curve were able to predict the tumor response in other experimental settings. The model can provide valuable information for planning the administration dose of radiopharmaceuticals in clinical trials, especially to determine the starting dose at which efficacy can be expected with a sufficient safety margin.

[1]  H. Enderling,et al.  Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system , 2022, Neoplasia.

[2]  T. Watabe,et al.  Comparison of the Therapeutic Effects of [211At]NaAt and [131I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model , 2021, International journal of molecular sciences.

[3]  M. Bandō,et al.  WAM to SeeSaw model for cancer therapy – overcoming LQM difficulties – , 2020, International journal of radiation biology.

[4]  U. Ganswindt,et al.  The Role of Cancer Stem Cells in Radiation Resistance , 2020, Frontiers in Oncology.

[5]  W E Bolch,et al.  ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals , 2019, Annals of the ICRP.

[6]  T. Watabe,et al.  Enhancement of 211At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer , 2019, The Journal of Nuclear Medicine.

[7]  Eduardo G Moros,et al.  The future of personalised radiotherapy for head and neck cancer. , 2017, The Lancet. Oncology.

[8]  F. Mottaghy,et al.  225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[9]  European Society of Radiology Summary of the European Directive 2013/59/Euratom: essentials for health professionals in radiology , 2015, Insights into Imaging.

[10]  Y. Yonekura,et al.  ICRP Publication 127: Radiological Protection in Ion Beam Radiotherapy , 2014 .

[11]  Eva Forssell-Aronsson,et al.  Biodistribution and dosimetry of free 211At, 125I- and 131I- in rats. , 2013, Cancer biotherapy & radiopharmaceuticals.

[12]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[13]  B. Wessels,et al.  MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy* , 2010, Journal of Nuclear Medicine.

[14]  Harald Paganetti,et al.  A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction , 2008, Physics in medicine and biology.

[15]  J. Hendry,et al.  Radiobiology for the Radiologist , 1979, British Journal of Cancer.

[16]  H. Song,et al.  Redefining Relative Biological Effectiveness in the Context of the EQDX Formalism: Implications for Alpha-Particle Emitter Therapy , 2014, Radiation research.

[17]  Y. Yonekura,et al.  Radiological protection in ion beam radiotherapy , 2014 .